$BHVN Biohaven: Q3 net loss $129.3M, cash ~$164.0M (Q3 2026)
Hub: https://www.merlintrader.com/biohaven-bhvn-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=bhvn
Not investment advice.
Hub: https://www.merlintrader.com/biohaven-bhvn-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=bhvn
Not investment advice.
November 10, 2026 at 6:30 PM
$BHVN Biohaven: Q3 net loss $129.3M, cash ~$164.0M (Q3 2026)
Hub: https://www.merlintrader.com/biohaven-bhvn-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=bhvn
Not investment advice.
Hub: https://www.merlintrader.com/biohaven-bhvn-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=bhvn
Not investment advice.
#$BHVN: Dark pool volume Nov 12: 0.4x its normal level, 5-day trend fading.
Dark pool shares by session (share of volume): Nov 13 404,069 (32.3%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Dark pool shares by session (share of volume): Nov 13 404,069 (32.3%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Biohaven (BHVN) Technical Levels: Options Flow Mixed Between $13.52 and $14.42
BHVN at $13.82: support $13.52, resistance $14.42; the chart, options flow and dark pools are mixed.
globaltradersacademy.com
November 13, 2026 at 10:43 PM
#$BHVN: Dark pool volume Nov 12: 0.4x its normal level, 5-day trend fading.
Dark pool shares by session (share of volume): Nov 13 404,069 (32.3%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Dark pool shares by session (share of volume): Nov 13 404,069 (32.3%).
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Full story at the link.
#darkpool #stocks #stockmarket
Biohaven Advances Research on Graves' Disease with New Trial and Presentations#USA#Philadelphia#Biohaven#BHV-1300#Graves'_Disease
Biohaven Advances Research on Graves' Disease with New Trial and Presentations
Biohaven sets a groundbreaking pace in Graves' disease treatment, launching a Phase 3 trial for BHV-1300 and three informative posters at the 2026 ATA meeting.
third-news.com
November 5, 2026 at 12:41 PM
Biohaven Advances Research on Graves' Disease with New Trial and Presentations#USA#Philadelphia#Biohaven#BHV-1300#Graves'_Disease
#BHVN Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Poste…
https://www.stocktitan.net/news/BHVN/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-w0gje9kzm7a2.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-w0gje9kzm7a2.html?utm_source=stocktitan-bluesky&utm_medium=social
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 12:30 PM
#BHVN Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Poste…
https://www.stocktitan.net/news/BHVN/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-w0gje9kzm7a2.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-drives-new-research-in-graves-disease-phase-3-pivotal-trial-w0gje9kzm7a2.html?utm_source=stocktitan-bluesky&utm_medium=social
#$BHVN weekly close $15.42 (+11.1% w/w), above SMA50 $13.62 / above SMA200 $12.23, RSI 61.1. Support $10.70, resistance $16.54. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/biohaven-bhv...
New hub updated: www.merlintrader.com/biohaven-bhv...
October 31, 2026 at 7:16 PM
#$BHVN weekly close $15.42 (+11.1% w/w), above SMA50 $13.62 / above SMA200 $12.23, RSI 61.1. Support $10.70, resistance $16.54. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/biohaven-bhv...
New hub updated: www.merlintrader.com/biohaven-bhv...
#$BHVN weekly close $15.42 (+11.1% w/w), above SMA50 $13.62 / above SMA200 $12.23, RSI 61.1. Support $10.70, resistance $16.54. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/biohaven-bhv...
New hub updated: www.merlintrader.com/biohaven-bhv...
October 31, 2026 at 7:16 PM
#$BHVN weekly close $15.42 (+11.1% w/w), above SMA50 $13.62 / above SMA200 $12.23, RSI 61.1. Support $10.70, resistance $16.54. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/biohaven-bhv...
New hub updated: www.merlintrader.com/biohaven-bhv...
Biohaven Advances Drug Development Through Strategic Partnerships and Financial Results Update#USA#FDA_Approval#Biohaven#New_Haven#VYGLXIA
Biohaven Advances Drug Development Through Strategic Partnerships and Financial Results Update
Biohaven has recently reported significant business developments, including FDA acceptance of a new drug application for Vyglxia and strategic collaborations boosting its financial position.
third-news.com
October 29, 2026 at 8:20 PM
Biohaven Advances Drug Development Through Strategic Partnerships and Financial Results Update#USA#FDA_Approval#Biohaven#New_Haven#VYGLXIA
#BHVN Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/BHVN/biohaven-reports-recent-business-developments-and-third-quarter-2026-9fzsnlklwzoc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-reports-recent-business-developments-and-third-quarter-2026-9fzsnlklwzoc.html?utm_source=stocktitan-bluesky&utm_medium=social
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 29, 2026 at 8:02 PM
#BHVN Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/BHVN/biohaven-reports-recent-business-developments-and-third-quarter-2026-9fzsnlklwzoc.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-reports-recent-business-developments-and-third-quarter-2026-9fzsnlklwzoc.html?utm_source=stocktitan-bluesky&utm_medium=social
Biohaven $BHVN reported Q3 2026 Adj EPS of -$0.73, missing the -$0.03 estimate by 2333.3%. Revenue of $0 missed the $110.0M estimate by 100.0%.
https://fundspec.ai/s/BHVN/earnings
Know who reports today, with an AI probability of a beat or a miss.
https://fundspec.ai/s/BHVN/earnings
Know who reports today, with an AI probability of a beat or a miss.
October 29, 2026 at 8:22 PM
Biohaven $BHVN reported Q3 2026 Adj EPS of -$0.73, missing the -$0.03 estimate by 2333.3%. Revenue of $0 missed the $110.0M estimate by 100.0%.
https://fundspec.ai/s/BHVN/earnings
Know who reports today, with an AI probability of a beat or a miss.
https://fundspec.ai/s/BHVN/earnings
Know who reports today, with an AI probability of a beat or a miss.
🚨 $BHVN
On October 29, 2026, Biohaven Ltd. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
On October 29, 2026, Biohaven Ltd. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
SEC Filing: BHVN
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 8:06 PM
🚨 $BHVN
On October 29, 2026, Biohaven Ltd. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
On October 29, 2026, Biohaven Ltd. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
$BHVN presented preclinical data for investigational BHV-1420 at ASN Kidney Week 2026.
Not investment advice.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
October 27, 2026 at 2:30 AM
$BHVN presented preclinical data for investigational BHV-1420 at ASN Kidney Week 2026.
Not investment advice.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
#BHVN Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remov…
https://www.stocktitan.net/news/BHVN/biohaven-oral-presentation-at-asn-kidney-week-2026-spotlights-bhv-mdpf959t1xfd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-oral-presentation-at-asn-kidney-week-2026-spotlights-bhv-mdpf959t1xfd.html?utm_source=stocktitan-bluesky&utm_medium=social
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
Biohaven (BHVN) presented preclinical findings for BHV-1420, its investigational antibody-removal treatment for membranous nephropathy, at ASN Kidney Week 2026.In a laboratory diagnostic assay, patient samples were mixed with BHV-1420 before testing; 88% of anti-PLA2R-positive samples (n=59) fell below the clinical threshold for positivity. This was a laboratory result, not a patient treatment outcome. In mice, a single subcutaneous dose of 4.8 mg/kg depleted circulating anti-PLA2R antibodies by more than 90% within two hours, sustained over the 72-hour study period. Biohaven designed BHV-1420 to direct these disease-driving antibodies to the liver for removal rather than suppress antibody-producing immune cells. It is the company's second TRAP kidney-disease program, alongside BHV-1400.
www.stocktitan.net
October 26, 2026 at 11:30 AM
#BHVN Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remov…
https://www.stocktitan.net/news/BHVN/biohaven-oral-presentation-at-asn-kidney-week-2026-spotlights-bhv-mdpf959t1xfd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/BHVN/biohaven-oral-presentation-at-asn-kidney-week-2026-spotlights-bhv-mdpf959t1xfd.html?utm_source=stocktitan-bluesky&utm_medium=social
$BHVN Latest company news, Oct 22, 2026: the FDA accepted the resubmitted NDA for Vyglxia (troriluzole) in spinocerebellar ataxia as a complete response to last year's letter.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
Biohaven $BHVN: FGFR3 ADC Data At ESMO 2026
Biohaven $BHVN: opakalim FDA partial hold, BHV-1530 oncology data, degrader trials, licensing, debt, cash needs and dilution risks.
www.merlintrader.com
October 22, 2026 at 6:50 PM
$BHVN Latest company news, Oct 22, 2026: the FDA accepted the resubmitted NDA for Vyglxia (troriluzole) in spinocerebellar ataxia as a complete response to last year's letter.
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
https://www.merlintrader.com/biohaven-bhvn-stock-hub/
#$BHVN went up 25.0% today to $14.69, with the FDA agreeing to review its rare disease drug again. 5 AI models have posted takes today and they're split. Bulls or bears from here?
BHVN: bull or bear?
Vote and see where the crowd and 5 AI models land on Biohaven Ltd..
buyorsellstocks.com
October 22, 2026 at 8:32 PM
#$BHVN went up 25.0% today to $14.69, with the FDA agreeing to review its rare disease drug again. 5 AI models have posted takes today and they're split. Bulls or bears from here?
→ What they did
Biohaven has received permission from the FDA to review its application for Vyglxia again, after it was previously rejected.
Biohaven has received permission from the FDA to review its application for Vyglxia again, after it was previously rejected.
October 22, 2026 at 6:00 PM
→ What they did
Biohaven has received permission from the FDA to review its application for Vyglxia again, after it was previously rejected.
Biohaven has received permission from the FDA to review its application for Vyglxia again, after it was previously rejected.
#Healthcare Biohaven Ltd. shares surged after the FDA accepted the company's resubmitted new drug application for Vyglxia (troriluzole), a treatment for spinocerebellar ataxia, with a PDUFA target decision date in the first quarter of 2027. The resubmission came after the FDA is ... Continue reading
October 22, 2026 at 9:35 PM
#Healthcare Biohaven Ltd. shares surged after the FDA accepted the company's resubmitted new drug application for Vyglxia (troriluzole), a treatment for spinocerebellar ataxia, with a PDUFA target decision date in the first quarter of 2027. The resubmission came after the FDA is ... Continue reading
🚨 $BHVN
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.
SEC Filing: BHVN
Click to view the official SEC document.
www.sec.gov
October 22, 2026 at 11:00 AM
🚨 $BHVN
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.